{"nct_id":"NCT06556563","title":"EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2025-02-03","start_date_type":"ACTUAL","primary_completion_date":"2029-04","primary_completion_date_type":"ESTIMATED","completion_date":"2029-04","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["NVCR"]}